Common Stock, par value $0.0001 per share
- Symbol
- NSPR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 1.01, 8.01, 9.01 · 8-K
NSPRNASDAQEQUITYCurrent
Item 1.01 Entry into a Material Definitive Agreement. On November 13, 2026, InspireMD, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as representative (the “Representative”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten public offe…
Press release in this filing
InspireMD Announces Pricing of $37.5 Million Public Offering →InspireMD seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.
InspireMD, Inc. · 8-K · Filed 2026-11-16
Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK INSPIREMD, INC. Warrant Shares: [●] Initial Exercise Date: November 16, 2026 ───────────────────────────────────────────────────────────── THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “ Warrant ”) certifies that, for value received, [●] or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “ Initial Exercise Date ”) until this Warrant is exercised in full (the “ Termination Date ”) but not thereafter, to subscribe for and purchase from InspireMD, Inc., a Delaware corporation (the “ Company ”), up to [●] shares (as subject to adjustment hereunder, the “ Warrant Shares ”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). Section 1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1: “ Affiliate ” means any Person that, directly or indirectly through one or more …
Open exhibit ↗Exhibit 4.2 SERIES L WARRANT TO PURCHASE COMMON STOCK INSPIREMD, INC. Warrant Shares: _______ Issuance Date: November 16, 2026 ──────────────────────────────────────────────────────── THIS SERIES L WARRANT TO PURCHASE COMMON STOCK (the “ Warrant ”) certifies that, for value received, [●] or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after November 16, 2026 (the “ Initial Exercise Date ”) and on or prior to 5:00 p.m. (New York City time) on November 16, 2027 (the “ Termination Date ”), but not thereafter, to subscribe for and purchase from InspireMD, Inc., a Delaware corporation (the “ Company ”), up to [●] shares (as subject to adjustment hereunder, the “ Warrant Shares ”) of Common Stock or Pre-Funded Warrants (as defined below) to purchase the same number of Warrant Shares (as subject to adjustment as provided herein). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). Section 1. Definitions. In addition to the terms defined elsewhere in thi…
Open exhibit ↗Exhibit 4.3 WARRANT AGENCY AGREEMENT THIS WARRANT AGENCY AGREEMENT (this “Agreement”), dated as of November 12, 2026, is entered into by and between InspireMD, Inc., a Delaware corporation (the “Company”), and Securities Transfer Corporation, a Texas corporation (the “Warrant Agent”). WHEREAS, the Company has filed with the Securities and Exchange Commission a Registration Statement on Form S-3, No: 333-286309 (the “Registration Statement”), for the registration, under the Securities Act of 1933, as amended (the “Act”), of, among other securities, (i) pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”), (ii) Series L warrants to purchase shares of Common Stock or Pre-Funded Warrants in lieu thereof (the “Common Warrants” and together with the Pre-Funded Warrants, the “Warrants”), and (iii) the shares of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) issuable upon exercise of the Warrants; WHEREAS, the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration, transfer, exchange and exercise of the Warrants; WHEREAS, t…
Open exhibit ↗Exhibit 99.1 InspireMD Announces Pricing of $37.5 Million Public Offering Miami, FL -- November 13, 2026 - InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the pricing of its previously announced underwritten public offering of (i) 7,342,308 shares of its common stock, (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase 50,350,000 shares of its common stock, and (iii) accompanying common warrants to purchase 43,269,231 shares of its common stock (or pre-funded warrants in lieu thereof). All securities in the offering are being offered by InspireMD. In addition, the Company granted the underwriters a 30-day option to purchase additional 8,653,846 shares of the Company’s common stock and/or 8,653,846 pre-funded warrants and/or additional common stock warrants to purchase 6,490,384 shares of common stock (or pre-funded warrants in lieu thereof) (or any combination thereof), representing 15% of the total number of shares of common stock and pre-funded warrants sold in the offering, solely to cover over-allotments, if any. The offering is exp…
Open exhibit ↗